Skip to main content
. 2023 Jan 13;24(2):1616. doi: 10.3390/ijms24021616

Figure 5.

Figure 5

In vivo targeting of proNGF in a mouse model of GBM. A xenograft mouse model of GBM was used. The human U87MG cells were injected subcutaneously between the shoulder blades of BALB/c nude mice, along with blocking anti-proNGF antibody (12 μg, intratumoral injection, twice a week for 4 weeks) and/or TMZ (50 mg/kg body weight, IP daily for 5 days) treatment for a 4-week course. (A) Representative photographs of U87MG tumors excised from mice after 4 weeks of treatment. Scale bar, 5 mm. (B) The growth curves of U87MG tumors in BALB/c nude mice (n = 9 for each group). (C) Comparison of volume of U87MG tumors harvested from mice treated with blocking anti-proNGF antibody and/or TMZ for 4 weeks. (D) Kaplan-Meier survival curves of BALB/c nude mice treated with anti-proNGF antibody and/or TMZ. Vehicle control vs. anti-proNGF: p = 0.0639; Vehicle control vs. TMZ: p < 0.0001; Vehicle control vs. anti-proNGF + TMZ: p = 0.0003; Anti-proNGF vs. anti-proNGF + TMZ: p = 0.0160, TMZ vs. anti-proNGF + TMZ: p = 0.8515. Data shown are the mean ± SD of tumors with 9 mice per treatment group. ProNGF: precursor for nerve growth factor, TMZ: Temozolomide. Vehicle control: PBS (vehicle control for anti-proNGF) + 5%GMSO + 30% Polyethylene glycol 300 (PEG300) + double-distilled H2O (vehicle control for TMZ); anti-proNGF: anti-proNGF + 5%GMSO + 30% PEG300 + double-distilled H2O (vehicle control for TMZ); TMZ: TMZ + PBS (vehicle control for anti-proNGF); anti-proNGF + TMZ: anti-proNGF + TMZ.